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Abstract
Taken as prescribed, that is, with high adherence, combination antiretroviral therapy (ART) has changed HIV
infection and disease from being a sure predictor of death to a manageable chronic illness. Adherence, however,
is difficult to achieve and maintain. The CAPRISA 058 study was conducted between 2007 and 2009 to test the
efficacy of individualized motivational counselling to enhance ART adherence in South Africa. As part of the
overall trial, a qualitative sub-study was conducted, including 30 individual interviews and four focus group
discussions with patients in the first 9 months of ART initiation. Data were inductively analyzed, using thematic
analysis, to identify themes central to ART adherence in this context. Four themes emerged that characterize the
participants’ experiences and high motivation to adhere to ART. Participants in this study were highly moti-
vated to adhere, as they acknowledged that ART was ‘life-giving’, in the face of a large amount of morbidity
and mortality. They were further supported by techniques of routine remembering, and highlighted the im-
portance of good social support and access to supportive healthcare workers, to their continued success in
negotiating their treatment. Participants in the current study told us that their adherence motivation is enhanced
by free accessible care, approachable and supportive healthcare workers, broad social acceptance of ART, and
past first-hand experiences with AIDS-related co-morbidity and mortality. Programs that include specific at-
tention to these aspects of care will likely be successful in the long term.
Introduction
Adherence to antiretroviral therapy
The success and impact of antiretroviral therapy (ART)has transformed human immunodeficiency virus (HIV)
infection and disease from a terminal illness to a manageable
chronic illness.1,2 Taken as prescribed, that is with high levels
of treatment adherence, combination ART leads to improved
immune functioning, with a decreased risk of progression to
AIDS and death.3 ART is not only important for physical
wellbeing, but has been associated with an increased proba-
bility of being at work within 6 months of starting therapy in
Uganda, and elsewhere in Africa.4
The key to effective ART treatment is patient adherence
and retention in care. Patient adherence is the percentage of
pills taken correctly as prescribed over a defined time period.
It has been estimated that for HIV treatment to be effective
adherence of at least 95% is required.5 While it is debatable
whether this very high level of adherence is necessary for all
ART drug combinations, viral suppression has been seen in
lower levels of adherence for the more potent non-nucleoside
reverse-transcriptase inhibitor-based therapy or in boosted
protease inhibitor therapy,6,7 it is nonetheless accepted that
for ART to work the highest level of adherence possible is a
desirable goal. Inadequate levels of adherence may lead to
the development of drug resistance and treatment failure,
1The Global Health Network, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
2London School of Hygiene and Tropical Medicine, London, United Kingdom.
3University of Winchester, Winchester, United Kingdom.
4CAPRISA, University of KwaZulu-Natal, Durban, South Africa.
ª van Loggerenberg 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under
the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited.
AIDS PATIENT CARE and STDs
Volume 29, Number 5, 2015
Mary Ann Liebert, Inc.
DOI: 10.1089/apc.2014.0293
299
with very serious consequences for the individual and the
treatment programme as a whole.8–11
Studies that focus on adherence to ART in Africa, and other
resource-constrained countries, suggest that good adherence
depends on timely and frequent clinic attendances and retention
in care programmes, which present particular challenges to
patients in these settings.12 Retention within treatment brings
with it the cost of transport to clinics, time away from essential
functions such as work, and user costs and fees that for patients
may be unsustainably high.13–16 Studies in Uganda, Burkina
Faso, and Mali demonstrated that distance to the clinic, and
related high transport costs, are risk factors for insufficient
access to care and inadequate viral suppression (‡ 500 copies/
mL after at least 6 months of treatment).17,18 Additionally, a
key review of ART adherence in Africa and Brazil highlighted
that self-funded ART is associated with poor adherence, as
either inadequate regimens are purchased, or prescriptions are
filled erratically.19 This review also found that in countries
where costs fell, adherence tended to improve.
Alongside the costs involved, factors that further impact
ART adherence are alcohol abuse, lack of adequate counsel-
ling, long waiting times for results, and poor provider-patient
relationships.20,21 Fear of stigma, especially from sexual part-
ners, and low rates of disclosure were significant in South
African studies.22 Being able to collect, store, and correctly
take HIVmedicine consistently over time in secret and without
social and material support is likely to be very difficult, and so
disclosure to at least one other trusted person is seen to be a very
important component of good adherence and is the foundation
of the treatment supporter approach to ART.23 Being able to
disclose to someone who does not react negatively can reduce
perceived stigma, and feeling less stigmatised may mean that
individuals are more likely to disclose their status voluntarily,
in order to receive much needed support and to improve ad-
herence.24,25 In this sense then, disclosure to at least one other
supportive person, who is able to provide material and/or social
support, is seen as important, and full disclosure may not be
necessary to improve treatment adherence, and may even be
undesirable where this may lead to increased stigma and dis-
crimination from unsupportive people.26
In South Africa, higher rates of disclosure tended to be as-
sociated with good adherence. However, such disclosure was
often difficult for patients to negotiate. For example, if partici-
pants feared being stigmatized by their sexual partner, then they
are significantly less likely to disclose their HIV status and report
that they were adherent. Moreover, research from the Western
Cape province of SouthAfrica found that alcohol abuse in family
members is often a key limiter to disclosure, in that it was dif-
ficult to trust someone who used alcohol to be discreet.23
Other qualitative studies from Africa have suggested that
higher levels of adherence may be related to the motivation to
be able to provide for families under difficult conditions.14 In
some African cultures, on-going treatment in the face of re-
solved symptoms may seem foreign.15 Finally, concerns
about food security, and being able to support improved ap-
petites from successful treatment, have also been raised as
barriers to treatment adherence.16
The Current Study
Data for this qualitative study were collected as part of a
randomized control trial (RCT), CAPRISA 058, which aimed
to test the efficacy of an individualized motivational coun-
seling intervention to enhance ART adherence.27 We con-
ducted this RCT in response to concerns that, due a lack of
political support for HIV treatment and, more damagingly,
explicit support of nutritional supplements, vitamins, and
other means of ‘treating’ HIV,28–30 patients may believe that
that ART was no better than these ‘treatments’ or even poi-
sonous.31 The majority of our participants were also enrolled
on a programme to integrate HIV and tuberculosis (TB)
treatment, since active TB is often a common entry point for
HIV testing and ART initiation.32 We were concerned that
the increased pill burden, the potential for greater side effects,
and the fact that they have different treatment regimes, could
all negatively impact on HIV treatment adherence.
In response to these concerns, an enhanced adherence support
intervention was developed (described in the parent study27).
The primary study showed that the participants who received
enhanced adherence support had no greater virological sup-
pression at 9 months than the control arm participants (87.9%
vs. 89.8%, p=0.62). Additionally, therewas no difference in the
proportion of people in each arm who achieved > 95% adher-
ence by pill count at 6 months (79.5% vs. 82.9%, p=0.51).
Importantly, all patients—including those in the control arm
who received standard adherence support—achieved unex-
pectedly good levels of adherence and treatment outcomes. In
this article, we explore how and why these patients had man-
aged to maintain such high levels of adherence, through an
analysis of qualitative data to provide insight into their moti-
vations, strategies, and experiences of ART, as well as to
evaluate the validity of the quantitative results in this context.33
Methods
Design
The data for this qualitative study were collected through
interviews and focus groups with patients scheduled for their
9-month post-treatment initiation clinic visit in both study
arms. Participants not selected for interviews but willing to
take part in focus group discussions were invited to do so,
during this same period. Data were collected by a staff
member working on HIV prevention studies at the clinic, but
not on the current study or on the treatment programme. This
was done in order to promote more open and honest reflection
by patients of their treatment at the clinic as, if someone
working on the treatment programme collected the data,
participants might feel pressure to present their treatment
experiences and adherence behavior in favorable light.
The interviews were semi-structured, consisting of a series
of broad open-ended questions, which the interviewer was
encouraged to prompt.34 These included questions about
personal experience of taking ART, personal adherence
strategies, examples of non-adherence, experiences of the
level of care at the clinic, side effect experiences, experiences
and attitudes towards disclosure, and other community re-
sources relating to adherence support. A final section of the
guide dealt with questions relating to more private behaviors,
such as drug and alcohol use, as well as sexual behavior. The
language was permissive to encourage discussion around
non-adherence. Talking about unanticipated issues was en-
couraged, and the interviewer was trained to facilitate this.
The four focus groups were conducted to encourage inter-
action more akin to everyday (and more social) conversation,
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and they have also been found to allow participants to express
views that are more critical than those presented in individual
interviews.35 This was seen to be especially useful in assessing
experiences at the treatment clinic, as views critical of the care
provided at the clinic would be important to assessing the value
of the adherence support.
Participants
30 patients consented to take part in individual interviews, 14
with control arm participants and 16 with intervention arm
participants. The interviewees consisted of 13 males (mean age
39.5 years, SD 7.3) and 17 females (mean age 34.8 years, SD
6.3). Six of the men and eight of the women were in the control
arm. Four focus groups were conducted with four participants
in each focus group. The composition of the groups depended
on which participants were available on the day. Three of the
four focus groups consisted of intervention arm participants;
one was all male, one all female, and one mixed. The group
consisting of control arm participants was of mixed gender.
Data collection and analysis
All interviews and focus groups were conducted in isiZulu,
the language of preference for all participants, and were
digitally recorded, transcribed, and translated into English.
The English transcripts constituted the study data.
Data were analyzed in NVivo 8.0, using thematic analysis,
which is a methodology aimed at capturing patterns in data,
guided by six phases of coding.36 Transcripts were coded by
two of the authors (Francois van Loggerenberg and Debra
Gray) independently and, at the time of coding, the allocation to
intervention or control arm was hidden, as was any other par-
ticipant demographic information. First, the transcripts were
read, and re-read for evidence of adherence strategies and ex-
periences regarding adherence, and initial codes were noted.
The codes were then organized into potential themes, which
were then reviewed to see if these themes were relevant to the
whole dataset. Emerging themes were identified as being ‘key’
if they were common across the sources, as well as if important
information in relation to adherence to ART was discussed by
participants, even if this was not prevalent in the dataset. So, for
example, negative experiences with adherence were very un-
common but considered key as they were very informative
about the overall lack of issues experienced by participants.
Finally, the two independent analyses of the data were com-
bined and compared. There was a high level of consistency
between the two analysts, and the four themes that emerged
most clearly from both analyses are presented below.
Results
Given that no differences in adherence and viral load
outcomes were found between the two arms in the primary
study trial, the findings presented below do not compare
participants’ experiences of these different forms of coun-
seling. Rather, we concentrate on the ways in which partic-
ipants across both counseling groups reported and negotiated
the various challenges and issues related to taking and ad-
hering to ART. We focus here on four themes that relate to
important aspects of these participants’ experiences of ART
adherence: ‘ART is for Life,’ ‘Routine Remembering,’
‘Support and Disclosure,’ and ‘Good Clinics, Good Carers.’
ART is ‘for life’
Across the data, many participants spoke of a strong per-
sonal motivation to adhere to their treatment regime, and it
was clear that this motivation was linked to the idea that ART
was ‘for life’—that is, the medication was described by
participants as ‘life-giving’ and, therefore, as a ‘life-long’
commitment. Consider the following extracts:
Extract 1 (Focus Group 4, Control Arm, Participant 4):
I have noticed how beautiful I have become after taking these
tablets—I don’t think I will ever stop taking them. I was sick, I
was very sick, I’m not exaggerating.I was raised from the
dead.
Extract 2 (Focus Group 1, Intervention Arm, Participant 4):
You can’t stop taking these tablets because.like me, they
woke me up from the grave. They are now my life. I will only
stop taking them when I’m dead, when I’m no more, because
they are my life.
These extracts demonstrate the ways in which, for these
participants, adhering to ART is understood to be a ‘life-or-
death’ matter; an understanding that in turn exerts very strong
motivational push on participants to remain on their medi-
cation. As in Extract 1, this link between ART and ‘life’ was
typically attributed to the transformative effects of the med-
ication—from a state of being ‘sick’ to one of health—and
many participants spoke about how taking the medication has
effected very real bodily transformations (e.g., on eating,
sleeping, tiredness, and appearance) that are taken as evi-
dence for the life-giving force of ART.
For many participants, even the side-effects of ART’s
(such as diarrhea, nausea, and transient dizziness), which
have been documented elsewhere as barriers to adherence,
were seen as manageable relative to the ill-health experi-
enced prior to starting ART.37,38 For example, when asked
whether she had ever thought of not taking her medication
one participant noted: ‘I once thought of that when I started
taking them, when I was still experiencing side effects but I
asked myself if I stop them, how am I going to live (Interview
7, Female, 36 years, Control Arm).
While the notion that ‘ART is for life’ did seem to suc-
cessfully motivate adherence behavior in these participants, it
also seems that the life-long commitment of ART can act as a
barrier to starting treatment in the first place. For example, the
following participant is discussing how she didn’t take her
tablets for the first couple of days after she was first given
them:
Extract 3 (Focus Group 1, Intervention Arm, Participant 2):
There was a time when I didn’t drink them. I didn’t take them
on the first day that I was supposed to take them. They asked
me if I was going to take them, I said, ‘‘yes I was going to take
them.’’ I took them and put them aside, I didn’t drink them.
What came to my mind at that time was that they say once I
start taking ARVs, I would have to take them for the rest of my
life. I asked myself ‘‘until when would I take these tablets?’’ I
was scared.
For some participants, this fear is clearly linked to a variety
of socially produced and widely available myths about ART
in the communities in which they live, for example, the idea
that ART results in poor health, makes you die faster, and that
it is stopping the tablets that make you die (rather than the
HIV)—reinforced by the metabolic complications of treat-
ment.39 Such social myths may constitute a potential barrier
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to others coming forward, being tested and starting treat-
ment.40 It may be that these misunderstandings of ART may
constitute a barrier to correct ART adherence in populations
with less access to counseling and other forms of support.
Routine remembering
Forgetting to take pills is often cited as a reason for non-
adherence. Indeed, in unpublished quantitative data from
the primary study, nearly 38% of participants (34/90) who
acknowledged missing doses indicated that this was due to
simple forgetting. However, in these qualitative data from
the study, very few participants talked about having any
problems with remembering to take their pills. Instead,
participants spoke of a variety of practical strategies that
allowed them to remember to take their medication in a
highly routine way—often using multiple strategies simul-
taneously.
By far the most popular reminder related to cell phone or
clock alarms which alone accounted for half of the around 40
individual strategies mentioned. Having someone remind
them to take their pills accounted for a quarter of these
strategies. Linking pill taking to popular TV programmes
(such as popular local soap operas) was also noted by some
participants, whilst others linked their pill taking to other
daily routines (e.g., taking the pills directly after waking).
The follow extract is typical of the way in which participants
describe their efforts to remember to take their medication,
including the ease with which they describe this being done:
Extract 4 (Interview 24, Female, 47 years, Control Arm):
I make sure that I eat my supper at seven, then at nine I take my
tablets. And I also make sure that I set alarm on my phone to
make sure that it reminds me at this time to take my tablets.
Also this box I received from the clinic where I put my tablets,
it also reminds me of the days, I make sure that I don’t miss
any day without taking my tablets.
For many, this process was made easier by the fact that
they had been on TB medication prior to starting ART. For
example, this participant who previously had to be on TB
treatment typifies how TB treatment experience may support
ART adherence:
Extract 5 (Interview 8, Male, 39 years, Intervention Arm):
I had no fears about ARVs because I’m used to taking tablets. I
have taken too many tablets in my life. And the tablets I am
taking now are far less because I only take four tablets.
In general, participants described adherence as being a
process of habituation—as something that they had to get
used to and have to ‘work with’ before arriving on a suc-
cessful routine. For example, some participants did report
that they had problems remembering to take their medication
exactly on time when they first started—a problem that was
often resolved by changing their medication routine (e.g., the
time that they took it) or their daily routine (e.g., the time they
went to bed) to something that worked for them. Clearly, the
counter to this highly routine and habitual form of remem-
bering is that any deviation from a normal daily routine will
clearly lend itself to forgetting. However, these participants
appeared to successfully negotiate and cope with this possi-
bility with relative ease. For example, as one participant re-
ports: ‘It’s in my system now, I know exactly time to take my
treatment (Focus group 4, Participant 3).
Support and disclosure
Across the data sources, many participants described how
it was important for them, and, others to disclose their HIV
status. Disclosure was not quantitatively assessed in this
study, and it cannot be presumed that the majority of par-
ticipants in the study had disclosed, or that self-reported
disclosure reflected actual disclosure rates. However, it was
clear that most participants did see disclosure as an important
facilitator for adherence—both directly in the sense that other
people could remind participant to take their medicine (as in
Extract 4 above), and indirectly in the sense that other people
were seen as key to reducing the stress on treatment patients.
For example:
Extract 6 (Focus Group 2, Participant 2):
It is important to have at least one person who knows so that
she can remind you. Even if you don’t live together, she can
even buzz you on the phone to remind you that it’s about time
to take your medicines. And also it helps to release stress
because you don’t have to carry the burden that is eating only
you inside.
However, participants still reported some concerns about
disclosing their HIV status to others. This is unsurprising
given that these participants live within communities and
contexts where stigma and discrimination against HIV pos-
itive individuals is high.26,41 Indeed, several participants
expressed concern that being on ART was still associated
with immoral behavior in communities and that they were
afraid of being victimized, or being ostracized from their
communities. Others indicated that they did want to be
blamed as the person who brought HIV to a relationship. In
part, these issues are related to the extent of gender-based
violence associated with HIV infection in southern Africa,
which is clearly a barrier to disclosure.25,42,43
Generally, participants recognized that non-disclosure
made it difficult to adhere to treatment regimes, for example,
through having to hide pill-taking, missing clinic appoint-
ments, or not being able to discuss condom use to prevent re-
infection, which was seen as key to continued health. Some
participants also talked about how they found that it was
easier to hide their HIV treatment if they had previously
disclosed their TB status. For example, one participant talked
about how they were able to avoid using alcohol by referring
to how sick they were with TB, and another participant was
able to use her TB treatment to ensure that her partner used
condoms, even though he was not yet aware of her HIV
status.
It is important to note that, while many participants did
express these wider concerns about disclosure, some partic-
ipants viewed disclosure as a positive community action.
Particularly that disclosure to the right people at the right
time was a strategy for ensuring that individuals accessed
treatment when needed. Indeed, many participants had stories
to tell about how their own openness had positive conse-
quences for getting other people onto treatment. Participants
who have done well on ART may feel a responsibility to the
community to ensure that the misconceptions about treatment
are dispelled and that they are examples of how well treat-
ment can work.
Finally, while few interviewees felt that disclosure was not
desirable, there were some exceptions to this, and their views
are informative. The following participant related a negative
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outcome to testing and disclosure, which motivated current
non-disclosure.
Extract 7 (Interview 14, Male, 41 years, Control Arm):
I told myself that, since both myself and her came together for
test at this clinic, I thought she was going to accept it but in the
end she couldn’t accept it. I was scared of people in such a way
that most people don’t even know that I have this disease. I
kept it to myself and I’m taking care of myself. I also make
sure that I take my tablets because I don’t want many people to
know because if I get sick, they will end up knowing because
doctors will report that it’s because I’m not taking the treat-
ment correctly, hence I’m getting sick.
Ironically, the fear of appearing ill and therefore being
known to be sick was motivating for this participant to adhere
to treatment. The motivational or adherence-enhancing po-
tential of fear of disclosure would need to be weighed against
the significant difficulties associated with taking medication
correctly, but covertly.
Good clinic, good carers
All of the participants talked about the quality of care they
receive at the research clinic and how important this was to
their treatment, adherence, and general well-being. It is clear
that this may (at least in part) be because these participants
felt some pressure to be positive about the programme in an
interview or focus group format. However, what is perhaps
most interesting about these accounts is not their endorse-
ment of the clinic, but the kinds of things that they saw as
being helpful to their continued adherence and health. For
example, several patients indicated that it was important that
the research clinic was a place of (nonjudgmental) empathy
and support. The fact that this facility is a dedicated HIV
treatment clinic meant that participants felt comfortable be-
ing together in the waiting room. They also felt that staff had
been well trained to be sensitive to HIV patients. Similarly,
several patients noted that the clinic staff had helped them to
understand their medication and treatment regimes, thereby
making it easier for them to understand what they had to do
and why. Nearly all of the participants also commented on the
range of additional services that the research clinic provided,
for example, tracking and tracing by phone call, delivering
pills to their home, or providing a taxi service if they needed
to come to the clinic—all of which were seen as essential to
their continued treatment success.
Across the focus groups and interviews, it was clear that
patients trusted the clinic staff. This is in turn meant that they
were able to go to the staff with issues and concerns. For
example, when asked about side effects a majority of patients
mentioned that they either had or would tell the nurse or
doctor about them, which meant they could be resolved
quickly and relatively easily. For example:
Extract 8 (Interview 7, Female, 36 years, Control Arm):
Yeah, they troubled me somehow, in a way that they drugged
me, at night I will have bad dreams, you know such things. But
I decided to continue because they had explained to me that
the treatment would do that initially but it will go away. So I
didn’t decide to stop them just because I was experiencing all
those things, but instead I continued taking them.
Similarly, the two participants in the study who did indi-
cate that they had any problem with adherence reported that
they returned to the research clinic to tell the clinic staff, at
which point they received additional counseling about the
importance of adherence from both the doctor and the
counselor.
For many participants, the high levels of care described
above were directly contrasted with the perceived and ex-
perienced standard of care found in public sector clinics in
South Africa. One participant described this process in terms
that are actually very damaging, and illegal:
Extract 9 (Focus group 2, Intervention Arm, Participant 1):
I would say it is very good and respected because they know
our status. We don’t have a problem with them and we are not
scared of them. In other places they shout at you in front of
everyone. Sometimes people wake up in the early hours of the
morning and they have to pay the nurse so that she can give
them their files to take the front row. If you don’t pay even if
you come in the morning, you can sit on the queue forever. I
accompanied my friend and we arrived in the morning, we
were told that those who come late have to pay to get their files
and if you pay then they put your file on top and the other at the
bottom. So there is no respect at all. They have an attitude
towards you as if you deliberately choose to be HIV positive.
For our participants, there was a general perception that
patients at other clinics did not do as well (and at times died)
due to the care received, even where they were on ART.
Additionally, some participants felt that the medication used
in the study clinic was more effective than treatments given
elsewhere. This idea may have arisen because the pills given
at the study clinic were once-a-day regimens, tailored to be
compatible with TB treatment, and not exactly the same
regimen as that given at the public health clinics.
Discussion
Given the expected complexity of ART in the context of
high levels of TB treatment, the good treatment and adher-
ence outcomes found in this study were unexpected. Our data
suggest that this is primarily because the participants had
very strong ‘life or death’ motivations to adhere, had devel-
oped highly routinized ways of remembering, relied on dis-
closure to key others, and relied on the clinic staff and
procedures to help them to remember to take their pills and
take them correctly.
The ‘life or death’ motivation of these patients may well be
because participants had experienced the deaths of others, or
had experienced what it is like to be very ill and not have
access to treatment. Therefore these participants valued the
treatment more than in other contexts where access may be
easier, and options more prolific. With such high levels of
expressed motivation, it is not surprising that efforts to im-
prove motivation in the intervention arm were unable to lead
to greater levels of treatment success in that arm. The phys-
ical transformation from ‘sick’ to ‘well’ (or from ‘death’ to
‘life’) is an important aspect in continued adherence in our
participants, and has been found to be a key component of re-
establishing social support networks in other populations, as
in Nigeria, for example.44
Participants report that TB treatment was a useful way to
access HIV diagnosis and treatment, which is an important
contribution of this study. For many participants, being ad-
herent to HIV treatment was seen as being easier because they
had already had some experience of routine pill taking and
were therefore less likely to forget to take their pills, or because
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it helped them to hide their HIV treatment from others. Thus, it
would seem that treatment for TB—which may be less stig-
matized and stigmatizing than treatment for HIV—can provide
patients with ways of being covertly adherent.
It is clear that the adherence support provided to patients
by the clinic is key to their retention in care and, therefore,
adherence success, and this is amenable to improvement in
clinics where participants are not managing to adhere to their
treatment. On the one hand, this relates to the counseling
support, which was clearly successful in engendering highly
routinized remembering, as well as providing key skills that
enabled patients to overcome specific issues relating to non-
adherence (e.g., side-effects, missed clinic visits, alcohol
use). This also relates to the various forms of practical sup-
port provided. The research clinic offered very efficient
tracking and tracing procedures, and was also very centrally
situated, with easy access to key public transport routes.
Thus, participants are likely to have experienced fewer
transportation issues than might have been the case if the
clinic had been in a more remote area.17,18 Some compen-
sation was also paid to those participants enrolled in research
studies at the site, to assist with transport and for the extra
time spent at the clinic. This is very different to experiences
in the public sector, where patients may be asked to pay a
nominal amount for treatment; something which may be
further compounded by the need to pay bribes (e.g., to receive
preferential queuing, if these reports are substantiated).
Overall, it is highly likely that these various forms of
support were central to promoting consistent clinic atten-
dance and that retention in care as essential for continued
high adherence. It is well documented that where participants
have difficulty accessing medical care and services, they are
unlikely to be able to adhere to their medication and care
visits.17 Qualitative data fromNigeria, Tanzania, and Uganda
also suggest that missed visits, most often for unintentional
reasons, may lead to reluctance to return to the clinic, which
in turn leads to long-term disengagement with care.45 Simi-
larly, other studies in Africa and India have found that the
financial costs of treatment can impact, usually negatively, on
adherence.19,46,47 This means that the results of this study
may not be easily generalized to all clinics in South Africa (or
indeed other resource constrained settings), as the level of
support offered is not comparable to, for example, clinics in
more remote areas where transportation is a key issue.
A key strength of this study is that we used data from one of
a first wave of adherence RCTs in Africa, and did not rely
purely on self-reported measures of adherence, rather it in-
cluded viral load as the primary outcome, which in this
context was likely to be the best indicator of good treatment
adherence. In addition to the quantitative outcomes, this
study further improved the relevance of findings by including
a substantial qualitative study component, which has been
outlined here. These data provide a great deal of insight into
the outcomes of the RCT, information that would otherwise
be lacking in the standard quantitative approach, and show
the strength of a mixed-methods approach to understanding
behavioral interventions.33 Where the quantitative study re-
port outlines ‘what’ happened, this qualitative study is able to
fill in more of the ‘why’, from the lived experience of the
participants. The high levels of motivation and lack of serious
problems expressed in the qualitative data support and vali-
date the quantitative study outcomes.
The interviewees also were, on the whole, very positive
about their experiences at the clinic, which could also be due
the fact that within the healthcare system in South Africa,
access to ART was still problematic, and participants may
have been reticent to speak about any issues with ART pro-
vision as theymay have feared losing their access to treatment.
It should be noted that these data were collected at 9 months
post-initiation of ART, and treatment fatigue may yet set in,
but longer follow up was beyond the scope of this study.
Participants in the study told us that their adherence mo-
tivation is enhanced by free accessible care, approachable
and supportive healthcare workers, broad social acceptance
of ART, and past first-hand experiences with AIDS related
co-morbidity and mortality. Of these factors, the approach-
able and supportive healthcare environment is the one that is
most amenable to improvement to enhance the likelihood that
participants will be retained in care, and thus benefit the most
from the positive health outcomes that come from sustained
high adherence. Programs that include specific attention
these aspects of care will likely be successful in the long term.
The strong life or death motivation expressed by the par-
ticipants is clearly important in ensuring that participants
continued to take their treatment as prescribed, and at suffi-
cient levels of adherence in face of key personal challenges.
The danger being that as patients become more ‘well’ the
impact of thesemotivationsmay fade and long-term adherence
may be poorer as a result, which is something that would need
to be monitored in any successful treatment programme. The
negative and damaging perceptions of the public health sector
facilities are concerning, and should be explored further.
Finally, the finding that our participants found experience
with TB treatment facilitated entry and retention on the ART
treatment program, was unexpected but very reassuring for
the continued success of integrating TB and HIV treatment in
a setting like South Africa where both disease, and co-in-
fection, are very prevalent. This qualitative data is supportive
of quantitative data that indicates that integrated treatment is
preferable in this setting.48,49
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